Skip to main content
Signal8

HeartSciences Inc. (HSCS) Form 8-K — Nov 19, 2026

$HSCSForm 8-KItems 1.01, 9.01Filed Nov 19, 2026, 9:12 AM ET0001213900-26-122044Original filing

HeartSciences entered into an Equity Distribution Agreement with Maxim Group LLC on November 18, 2026, establishing an at-the-market program for up to $50,000,000 of common stock off its S-3 shelf declared effective November 17, 2026. Because HeartSciences is subject to General Instruction I.B.6 of Form S-3 (non-affiliate float under $75 million), the prospectus supplement filed November 19, 2026 covers only $3,077,649 of sales, despite the $50 million program size. Maxim earns a 2.5% commission on sales while the I.B.6 limit applies (2.0% thereafter), plus up to $15,000 in legal expense reimbursement and $5,000 per Bringdown Date.

Key figures

Gross Proceeds
50000000
Shelf capacity
$200,000,000
Bringdown date fee
$5,000
Commission pct standard
2.0%
Legal fee reimbursement
$15,000
Commission pct baby shelf
2.5%
Immediately available amount
$3,077,649

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.